Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - glycopyrronium bromide, quantity: 200 microgram - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. ,2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes. ,3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.

India - English - Central Drugs Standard Control Organization

shreeyam - ritodrine - tab - 10mg - 10

India - English - Central Drugs Standard Control Organization

shreeyam - ritodrine - inj - 10mg - 1ml

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

ritodrine hydrochloride usp 10mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

glycopyrrolate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes. 3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - glycopyrronium bromide 0.2 mg/ml - solution for injection - 0.2 mg/ml - active: glycopyrronium bromide 0.2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - glycopyrrolate is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions: to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anaesthesia and intubation when indicated. glycopyrronium bromide 200 micrograms per ml solution for injection may be used intraoperatively to counteract drug-induced or vagal traction reflexes with the associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g. bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarising muscle relaxants. for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sodium chloride - 1.as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2.as a preoperative or intraoperative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxa-methonium or due to cardiac vagal reflexes. 3.to protect against the peripheral muscarinic actions (eg. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by nondepolarising muscle relaxants.

New Zealand - English - Medsafe (Medicines Safety Authority)

miro healthcare limited - glycopyrronium bromide 0.2 mg/ml - solution for injection - 0.2 mg/ml - active: glycopyrronium bromide 0.2 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - glycopyrrolate indoco is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anaesthesia and intubation when indicated. glycopyrrolate indoco injectable may be used intraoperatively to counteract drug-induced or vagal traction reflexes with the associated arrhythmias. glycopyrronium bromide (glycopyrrolate) protects against the peripheral muscarinic effects (e.g. bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarising muscle relaxants.

Australia - English - Department of Health (Therapeutic Goods Administration)

glycopyrrolate -